Clinical Trials Logo

Alopecia clinical trials

View clinical trials related to Alopecia.

Filter by:

NCT ID: NCT01548066 Completed - Clinical trials for Androgenetic Alopecia

The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Beta-catenin, the transducer of Wnt signaling, is critical in development, growth, and regeneration of hair. In the absence of Wnt signals, cytoplasmic β-catenin is maintained at low level through regulation by GSK-3, multifunctional serine/threonin kinase. After phosphorylation by GSK-3, β-catenin is ubiquitinated and degraded in cytoplasm. Therefore, inhibition of GSK-3 is able to increase β-catenin in nucleus and would be able to induce growth of hair. Valproic acid (VPA) is an anticonvulsant and mood-stabilizing drug used for decades and is known to inhibit the GSK-3β. However, the effect of VPA on hairs has not been studied yet.

NCT ID: NCT01520077 Completed - Alopecia Areata Clinical Trials

Vytorin in the Treatment of Alopecia Areata

Start date: July 2011
Phase: Phase 1
Study type: Interventional

Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth. The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.

NCT ID: NCT01501617 Unknown status - Clinical trials for Androgenetic Alopecia

Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia

HSC Phase I/II
Start date: December 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men. HSC will be injected intradermally in the scalps of men with male pattern baldness (i.e. androgenetic alopecia).

NCT ID: NCT01453686 Completed - Alopecia Areata Clinical Trials

A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata

Start date: August 2002
Phase: Phase 3
Study type: Interventional

The use of topical steroids in the treatment of alopecia areata in children is common practice. However, no particular potency of steroid is accepted as the standard treatment due to the paucity of high quality evidence in the dermatology literature to substantiate their use. Two randomized controlled trials exist assessing topical steroid efficacy in this disorder, both have methodological limitations. The question remains as to which topical steroid is safe and efficacious for use. We performed a double blinded controlled trial to assess the usefulness of a class 1 topical steroid (clobestasol proprionate 0.05%) compared with a class 7 topical steroid (hydrocortisone 1%) in children with alopecia areata.

NCT ID: NCT01451190 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

Start date: July 2011
Phase: Phase 2
Study type: Interventional

Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.

NCT ID: NCT01451177 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)

Start date: May 2010
Phase: Phase 2
Study type: Interventional

Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.

NCT ID: NCT01451151 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.

NCT ID: NCT01451138 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the ability of injections of Ji Gami(TM) N and Ji Gami(TM) NDO to induce hair growth in male and female subjects with hair loss.

NCT ID: NCT01451125 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.

NCT ID: NCT01451112 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.